Contribute Try STAT+ Today

Hello, everyone, and welcome to the middle of the week. Under the circumstances, this is more of an accomplishment than usual, perhaps, so why not take a deep breath and enjoy a cup of stimulation? We have been favoring maple bourbon lately, a new addition to our cupboard. Feel free to join us. Remember, no prescription is required. Meanwhile, here is the latest menu of tidbits to start your day. We hope all goes well and that you all remain healthy. Stay safe and please do keep in touch.

The coronavirus is not mutating significantly as it circulates through the human population, according to scientists who are closely studying the novel pathogen’s genetic code, the Washington Post writes. That relative stability suggests the virus is less likely to become more or less dangerous as it spreads, and represents encouraging news for researchers hoping to create a long-lasting vaccine. Covid-19 has proofreading machinery and that reduces the “error rate” and the pace of mutation. It looks pretty much the same everywhere it has appeared.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Let’s just pick the once and future EpiPen issues – “Pfizer wrote in an email that the problems with the products’ safety release involved “a very limited number” of EpiPens, and only 0.0002% had the defective carrier tube.”
    A quick calculation translates that to 200 failures per million. Back of the envelope, Mylan sells over 3 Million per year, so over 600. The variance is what % are these failures of the EpiPens that are actually used? It that % deceptively small?

Comments are closed.